{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:30:54Z","timestamp":1789608654976,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To compare the incidence of hypertensive disorders of pregnancy among women living with human immunodeficiency virus (HIV) on combination antiretroviral therapy (ART) to women without HIV, and to evaluate the association of hypertensive disorders of pregnancy with ART regimens or timing of ART initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study among two overlapping pregnancy cohorts using preexisting databases at a single tertiary care hospital: all pregnant women who delivered during years 2016\u20132018 (cohort 1) and all women living with HIV who delivered during years 2011\u20132018 (cohort 2). The primary outcome for both cohorts was any hypertensive disorder of pregnancy; gestational hypertension and preeclampsia were also examined separately. The primary exposure variables were HIV status for cohort 1 and ART regimen (integrase strand transfer inhibitor\u2013containing, protease inhibitor\u2013containing, or non-nucleoside reverse transcriptase inhibitor\u2013containing) for cohort 2. For estimation of risk ratios (RRs), we used a modified Poisson regression with robust error variances. Multivariate models among the women living with HIV in cohort 2 were tested for a statistical interaction between ART regimen and timing of initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>In cohort 1, among 80 women living with HIV compared with 3,464 women without HIV, there was no difference in the risk of hypertensive disorders of pregnancy (29% in women living with HIV vs 30% in women without HIV, adjusted RR 0.9, 95% CI 0.6\u20131.3). In cohort 2, among 265 women living with HIV, integrase strand transfer inhibitor\u2013containing regimens were associated with an increased risk for any hypertensive disorder of pregnancy (25% among integrase strand transfer inhibitor vs 10% among protease inhibitor, adjusted RR 2.8, 95% CI 1.5\u20135.1) and gestational hypertension (20% among integrase strand transfer inhibitor vs 8% among protease inhibitor, adjusted RR 2.8, 95% CI 1.3\u20135.9) compared with protease inhibitor\u2013containing regimens. Timing of ART initiation was not associated with hypertensive disorders of pregnancy, nor did it significantly alter the associations between ART regimen and hypertensive disorders of pregnancy outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Overall the risk of hypertensive disorders of pregnancy was similar among women living with HIV on ART and women without HIV. With greater integrase strand transfer inhibitor use, the greater frequency of hypertensive disorders of pregnancy with these regimens compared with protease inhibitor\u2013containing regimens warrants future evaluation using cohorts with greater sample size.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003584","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:06:00Z","timestamp":1573067160000},"page":"1205-1214","source":"Crossref","is-referenced-by-count":35,"title":["Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy"],"prefix":"10.1097","volume":"134","author":[{"given":"Michele K.","family":"Saums","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna C.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi N.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Badell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise J.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"R2-20230811","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/hr.2016.126","article-title":"Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis","volume":"40","author":"Umesawa","year":"2017","journal-title":"Hypertens Res"},{"key":"R3-20230811","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"Say","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R4-20230811","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0140-6736(02)11195-0","article-title":"Pre-eclampsia, antiretroviral therapy, and immune reconstitution","volume":"360","author":"Wimalasundera","year":"2002","journal-title":"Lancet"},{"key":"R5-20230811","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijgo.2016.03.014","article-title":"A retrospective study of HIV, antiretroviral therapy, and pregnancy-associated hypertension among women in Lusaka, Zambia","volume":"134","author":"Stoner","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"key":"R6-20230811","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.preghy.2013.11.008","article-title":"Pre-eclampsia and gestational hypertension are less common in HIV infected women","volume":"4","author":"Hall","year":"2014","journal-title":"Pregnancy Hypertens"},{"key":"R7-20230811","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jinf.2013.12.018","article-title":"Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries","volume":"68","author":"Machado","year":"2014","journal-title":"J Infect"},{"key":"R8-20230811","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.aids.0000198090.70325.bd","article-title":"Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy","volume":"20","author":"Suy","year":"2006","journal-title":"AIDS"},{"key":"R9-20230811","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/AOG.0000000000001424","article-title":"Risk of preeclampsia in human immunodeficiency virus-infected pregnant women","volume":"127","author":"Sansone","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R11-20230811","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejogrb.2016.12.008","article-title":"The impact of highly active antiretroviral therapy on obstetric conditions: a review","volume":"210","author":"Sebitloane HM","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R12-20230811","doi-asserted-by":"crossref","first-page":"e1002706","DOI":"10.1371\/journal.pmed.1002706","article-title":"Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: a randomised controlled trial","volume":"15","author":"Kityo","year":"2018","journal-title":"PLoS Med"},{"key":"R13-20230811","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1093\/jac\/dkt183","article-title":"Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy","volume":"68","author":"Negredo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R14-20230811","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R15-20230811","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09540121.2017.1417531","article-title":"Long term engagement in HIV care among postpartum women with perinatal HIV infection in the United States","volume":"30","author":"Meade","year":"2018","journal-title":"AIDS Care"},{"key":"R16-20230811","first-page":"e1","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. American College of Obstetricians and Gynecologists","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R17-20230811","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"R18-20230811","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.preghy.2019.07.008","article-title":"Human immunodeficiency virus and risk of pre-eclampsia and eclampsia in pregnant women: a meta-analysis on cohort studies","volume":"17","author":"Nourollahpour Shiadeh","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"R19-20230811","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.preghy.2019.05.015","article-title":"Combined antiretroviral therapy for HIV and the risk of hypertensive disorders of pregnancy: a systematic review","volume":"17","author":"Premkumar","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"R20-20230811","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/hr.2016.152","article-title":"Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction","volume":"40","author":"Tomimatsu","year":"2017","journal-title":"Hypertens Res"},{"key":"R21-20230811","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"R22-20230811","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1345\/aph.1L689","article-title":"Adverse effects of antiretrovirals in HIV-infected pregnant women","volume":"43","author":"Zuk","year":"2009","journal-title":"Ann Pharmacother"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T19:04:14Z","timestamp":1691780654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003584","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,4]]}}}